Can atrial fibrillation lead to clot-related brain infarction and cognitive decline despite anticoagulation?

Atrial fibrillation (AF) creates a well-established cardioembolic pathway: impaired atrial contraction and remodeling can promote left-atrial-appendage thrombus, which may embolize to cerebral arteries and cause overt or MRI-detected infarction. For a 69-year-old man, the clinical relevance depends on overall thromboembolic and bleeding risk, AF pattern, and competing cerebrovascular causes.

Clinical and cognitive evidence

• AF-associated atrial thrombi can occlude cerebral arteries, producing ischemic stroke or clinically unrecognized (“silent”) infarcts. Individual infarcts in a person with AF should not automatically be attributed to AF; vascular imaging and cardiac assessment remain important.
• Anticoagulation materially reduces clinical stroke/systemic-embolism risk but does not eliminate it. Across 71,683 trial participants, standard-dose direct oral anticoagulants reduced events versus warfarin from 3.69% to 3.01% (HR 0.81, 95% CI 0.74–0.89); treated-patient annual event rates remained approximately 1.1%–2.1% across pivotal trials.
• Silent infarcts matter clinically: their presence was associated with later dementia (meta-analytic HR 1.48, 95% CI 1.12–1.97; 1.27 after excluding an outlier). In the Rotterdam Scan Study, baseline infarcts predicted dementia over 3.6 years (HR 2.26, 95% CI 1.09–4.70).

Mechanism and residual risk

• AF promotes Virchow-triad conditions: appendage blood stasis from ineffective contraction, plus dilation, fibrosis, endocardial dysfunction, and procoagulant/platelet-fibrinolytic changes. Anticoagulation limits thrombogenesis, explaining its stroke-prevention effect.
• Residual brain injury occurs despite treatment: in Swiss-AF, 5.5% developed new MRI infarcts over two years; 85% had no recognized stroke/TIA, and 75% of those affected were anticoagulated.

Bottom line

• The claim is supported: AF can cause atrial clot formation and cerebral embolism; anticoagulation substantially lowers clinical thromboembolic risk but leaves residual overt and silent infarction risk, and recurrent or strategically located infarcts can contribute to cognitive decline.